Payment overview · 2025
General Payments
$480.99
25 reported records · 10 companies
Healthcare provider profile · identity verified
William Herman Sessions, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FLEMING ISLAND, FL · NPI 1669471033
Verified facts
What the public records show
CMS Open Payments records show William Herman Sessions, M.D. received $480.99 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $165.47 | 34.4% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.19 | 16.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.37 | 12.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.00 | 8.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.38 | 6.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.19 | 5.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.14 | 5.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.72 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.40 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.13 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $480.99 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.90 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.19 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $71.38 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.98 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.37 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.19 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 190 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 377 | 62 |
| Gabapentin | Gabapentin | 320 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 116 |
| Lorazepam | Lorazepam | 243 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 81 |
| Alprazolam | Alprazolam | 219 | 39 |
| Lisinopril | Lisinopril | 218 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 216 | 51 |
| Losartan Potassium | Losartan Potassium | 210 | 77 |
| Omeprazole | Omeprazole | 199 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 67 |
| Furosemide | Furosemide | 181 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 178 | 29 |
| Metformin Hcl | Metformin Hcl | 176 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 62 |
| Clonazepam | Clonazepam | 152 | 26 |
| Potassium Chloride | Potassium Chloride | 149 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 46 |
| Sertraline Hcl | Sertraline Hcl | 147 | 37 |
| Tramadol Hcl | Tramadol Hcl | 143 | 44 |
| Simvastatin | Simvastatin | 142 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 48 |
| Alendronate Sodium | Alendronate Sodium | 120 | 47 |
| Carvedilol | Carvedilol | 117 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 35 |
| Trazodone Hcl | Trazodone Hcl | 114 | 33 |
| Ondansetron Odt | Ondansetron | 112 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 34 |
| Ozempic | Semaglutide | 104 | 25 |
| Temazepam | Temazepam | 103 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 33 |
| Finasteride | Finasteride | 99 | 36 |
| Eliquis | Apixaban | 98 | 28 |
| Buspirone Hcl | Buspirone Hcl | 94 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 20 |
| Jardiance | Empagliflozin | 87 | 22 |
| Allopurinol | Allopurinol | 82 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 26 |
| Meloxicam | Meloxicam | 74 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 72 | 20 |
| Donepezil Hcl | Donepezil Hcl | 72 | 25 |
| Glimepiride | Glimepiride | 72 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | 22 |
| Ibuprofen | Ibuprofen | 70 | 20 |
| Aripiprazole | Aripiprazole | 68 | 16 |
| Metformin Hcl Er | Metformin Hcl | 68 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 17 |
| Montelukast Sodium | Montelukast Sodium | 63 | 26 |
| Ezetimibe | Ezetimibe | 60 | 23 |
| Glipizide Er | Glipizide | 58 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 43 |
| Levetiracetam | Levetiracetam | 55 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 20 |
| Prednisone | Prednisone | 52 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Ketoconazole | Ketoconazole | 47 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 11 |
| Glipizide | Glipizide | 42 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 11 |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Naproxen | Naproxen | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 20 |
| Atenolol | Atenolol | 30 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 11 |
| Primidone | Primidone | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 13 |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Promethazine Hcl | Promethazine Hcl | 28 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Nateglinide | Nateglinide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Fentanyl | Fentanyl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Testosterone | Testosterone | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $480.99 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FARXIGA, JOURNAVX, KISUNLA, Korlym, REXULTI, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error